These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Substitution treatment in hemophilia. Critical measures and complications]. Schimpf K Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496 [No Abstract] [Full Text] [Related]
23. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia. McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730 [TBL] [Abstract][Full Text] [Related]
24. Specific therapy in hemophilia. Hutaff LW N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809 [No Abstract] [Full Text] [Related]
25. Current concepts in diagnosis and management of hemophilia. Aledort LM Hosp Pract (Off Ed); 1982 Oct; 17(10):77-84, 89-92. PubMed ID: 6811410 [No Abstract] [Full Text] [Related]
26. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors. Johnson AJ; Mathews RW; Fulton AJ Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Kulkarni R Haemophilia; 2013 Jan; 19(1):2-10. PubMed ID: 22925397 [TBL] [Abstract][Full Text] [Related]
30. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia. Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287 [TBL] [Abstract][Full Text] [Related]
31. Self-therapy for haemophilia in Norway. Effect on transfusion frequency and days lost from work. Evensen SA; Thaule R; Grøan K Acta Med Scand; 1979; 205(5):395-9. PubMed ID: 443078 [TBL] [Abstract][Full Text] [Related]
32. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia]. Pollmann H Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261 [TBL] [Abstract][Full Text] [Related]
33. Progress and problems in hemophilia and von Willebrand's disease. Abildgaard CF Adv Pediatr; 1984; 31():137-77. PubMed ID: 6440429 [No Abstract] [Full Text] [Related]
34. A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B. Stubbs M; Lloyd J Aust Dent J; 2001 Mar; 46(1):37-40. PubMed ID: 11355239 [TBL] [Abstract][Full Text] [Related]
35. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management. Mahasandana C; Patharathienskul D; Suvatte V Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549 [TBL] [Abstract][Full Text] [Related]
36. Current concepts in the management of hemophilia. Abildgaard CF Semin Hematol; 1975 Jul; 12(3):223-32. PubMed ID: 1079631 [No Abstract] [Full Text] [Related]
37. The management of patients with bleeding disorders. Wyld PJ; Dawson KP N Z Med J; 1984 Feb; 97(750):118-9. PubMed ID: 6424072 [No Abstract] [Full Text] [Related]
38. Preclinical and clinical gene therapy for haemophilia. Chuah MK; Collen D; Vandendriessche T Haemophilia; 2004 Oct; 10 Suppl 4():119-25. PubMed ID: 15479384 [TBL] [Abstract][Full Text] [Related]
39. Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors. Hanna WT; Madigan RR; Miles MA; Lange RD Thromb Haemost; 1981 Oct; 46(3):638-41. PubMed ID: 6976016 [TBL] [Abstract][Full Text] [Related]
40. [Treatment of hemophilias]. Fischer M; Deutsch E Dtsch Med J; 1968 Jul; 19(14):499-505. PubMed ID: 5305713 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]